Baxter International, Inc. (BAX) Presents Long-Term Data on HyQ During American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting
3/5/2012 6:08:13 AM
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) today announced the presentation of additional long-term data supporting the clinical profile of HyQ, its investigational combination product for use in patients with primary immunodeficiencies (PI). The company also introduced HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], as the submitted brand name for the investigational product, previously referred to as HyQ. Posters and oral presentations regarding the HyQvia clinical program will be given during the 2012 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual meeting in Orlando.